{"transactions":[{"id":833134,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-19T22:57:49.000Z","date":"2026-03-17","kind":"sale","planned":true,"acquired":false,"shares":2073,"price":99.4804,"value":206222.8692,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units (\"RSUs\") after March 15, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 62,050 RSUs."}],"balance_after":101366,"source":{"system":"sec-edgar","filing":"0001610717-26-000132","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000132/form4.xml","form_type":"4"}},{"id":865075,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T02:10:30.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the \"Vesting Commencement Date\"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":34000,"derivative":{"exercise_price":102.02,"expiration_date":"2036-02-28","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001610717-26-000084","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000084/form4.xml","form_type":"4"}},{"id":865074,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-04T02:10:30.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":15100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 68,000 restricted stock units."}],"balance_after":103439,"source":{"system":"sec-edgar","filing":"0001610717-26-000084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000084/form4.xml","form_type":"4"}},{"id":1036122,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-09-18T20:39:39.000Z","date":"2025-09-16","kind":"sale","planned":true,"acquired":false,"shares":2160,"price":45.8249,"value":98981.784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units (\"RSUs\") after March 15, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 58,850 restricted stock units."}],"balance_after":88339,"source":{"system":"sec-edgar","filing":"0001610717-25-000351","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071725000351/form4.xml","form_type":"4"}},{"id":1105949,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-06-18T20:05:01.000Z","date":"2025-06-16","kind":"sale","planned":true,"acquired":false,"shares":2173,"price":39.83,"value":86550.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units (\"RSUs\") after March 15, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $39.6017 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,021 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 64,800 RSUs."}],"balance_after":90499,"source":{"system":"sec-edgar","filing":"0001610717-25-000237","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071725000237/form4.xml","form_type":"4"}},{"id":1147592,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-05-15T16:34:37.000Z","date":"2025-05-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24100,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.93,"underlying":"Common Stock","underlying_shares":24100},"source":{"system":"sec-edgar","filing":"0001562180-25-003883","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218025003883/primarydocument.xml","form_type":"4"}},{"id":1147591,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T16:34:37.000Z","date":"2025-05-13","kind":"other","planned":false,"acquired":false,"shares":15267,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $5.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-25-003883","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218025003883/primarydocument.xml","form_type":"4"}},{"id":1147590,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T16:34:37.000Z","date":"2025-05-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17583,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $5.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."}],"balance_after":15267,"source":{"system":"sec-edgar","filing":"0001562180-25-003883","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218025003883/primarydocument.xml","form_type":"4"}},{"id":1226270,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-05T00:01:36.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":72800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the \"Vesting Commencement Date\"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":72800,"derivative":{"exercise_price":40.74,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":72800},"source":{"system":"sec-edgar","filing":"0001610717-25-000052","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071725000052/form4.xml","form_type":"4"}},{"id":1226269,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-05T00:01:36.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":false,"shares":20800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 70,750 restricted stock units."}],"balance_after":91651,"source":{"system":"sec-edgar","filing":"0001610717-25-000052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071725000052/form4.xml","form_type":"4"}},{"id":1472768,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-06-20T20:10:50.000Z","date":"2024-06-17","kind":"sale","planned":false,"acquired":false,"shares":5589,"price":37.3867,"value":208954.2663,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units (\"RSUs\") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $37.3867 to $37.3871, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,040 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 59,250 RSUs."}],"balance_after":70851,"source":{"system":"sec-edgar","filing":"0001610717-24-000347","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071724000347/form4.xml","form_type":"4"}},{"id":1482242,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-12T18:53:34.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":24100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":24100,"derivative":{"exercise_price":3.93,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":24100},"source":{"system":"sec-edgar","filing":"0001562180-24-005009","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218024005009/primarydocument.xml","form_type":"4"}},{"id":1482241,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-12T18:53:34.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units vest 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":32850,"source":{"system":"sec-edgar","filing":"0001562180-24-005009","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218024005009/primarydocument.xml","form_type":"4"}},{"id":1854616,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T17:00:44.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":8450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests 100% on the earlier of June 13, 2024 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":8450,"derivative":{"exercise_price":11.81,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":8450},"source":{"system":"sec-edgar","filing":"0001562180-23-005218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218023005218/primarydocument.xml","form_type":"4"}},{"id":1854615,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T17:00:44.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":4200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units vest 100% on the earlier of June 13, 2024 or the date of the next annual meeting of stockholders of 2seventy bio, Inc."}],"balance_after":20800,"source":{"system":"sec-edgar","filing":"0001562180-23-005218","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218023005218/primarydocument.xml","form_type":"4"}},{"id":1961234,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-09T21:48:00.000Z","date":"2023-03-07","kind":"grant","acquired":true,"shares":33400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option vests ratably over three years in annual installments with the first installment vesting on March 7, 2024, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":33400,"derivative":{"exercise_price":10.91,"expiration_date":"2033-03-07","underlying":"Common Stock","underlying_shares":33400},"source":{"system":"sec-edgar","filing":"0001562180-23-002688","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218023002688/primarydocument.xml","form_type":"4"}},{"id":1961233,"issuer":{"id":79756,"kind":"organization","name":"2seventy bio, Inc.","symbol":"TSVT"},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T21:48:00.000Z","date":"2023-03-07","kind":"grant","acquired":true,"shares":16600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This restricted stock unit award vests ratably over three years in annual installments with the first installment vesting on March 7, 2024, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":16600,"source":{"system":"sec-edgar","filing":"0001562180-23-002688","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860782/000156218023002688/primarydocument.xml","form_type":"4"}},{"id":2033148,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-03T13:53:58.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vest monthly following February 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":560000,"derivative":{"exercise_price":4,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001209191-23-006480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000120919123006480/doc4.xml","form_type":"4"}},{"id":2033147,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-03T13:53:58.000Z","date":"2023-02-01","kind":"other","acquired":true,"shares":2,"price":3.893,"value":7.786,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,748 shares acquired under the Erasca, Inc. Employee Stock Purchase Plan (the ESPP) on June 15, 2022 and 2 shares acquired under the ESPP on December 15, 2022."}],"balance_after":315812,"source":{"system":"sec-edgar","filing":"0001209191-23-006480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000120919123006480/doc4.xml","form_type":"4"}},{"id":2033146,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-03T13:53:58.000Z","date":"2023-02-01","kind":"other","acquired":true,"shares":1748,"price":4.097,"value":7161.556,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,748 shares acquired under the Erasca, Inc. Employee Stock Purchase Plan (the ESPP) on June 15, 2022 and 2 shares acquired under the ESPP on December 15, 2022."}],"balance_after":315812,"source":{"system":"sec-edgar","filing":"0001209191-23-006480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000120919123006480/doc4.xml","form_type":"4"}},{"id":2414192,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-04T00:54:57.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":272100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":272100,"derivative":{"exercise_price":11.54,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":272100},"source":{"system":"sec-edgar","filing":"0001209191-22-007065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000120919122007065/doc4.xml","form_type":"4"}},{"id":2414191,"issuer":{"id":3796,"kind":"organization","name":"Erasca, Inc."},"owners":[{"id":26518,"kind":"person","name":"Wei Lin","position":1,"cik":"0001872772","reported_name":"Wei Lin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-04T00:54:57.000Z","date":"2022-02-01","kind":"other","acquired":true,"shares":1562,"price":11.6025,"value":18123.105,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,562 shares acquired under the Erasca, Inc. employee stock purchase plan on December 15, 2021."}],"balance_after":314062,"source":{"system":"sec-edgar","filing":"0001209191-22-007065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1761918/000120919122007065/doc4.xml","form_type":"4"}}]}